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Episodic Ataxia Type 1 (K-channelopathy)
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Ion channels are transmembrane proteins that facilitate ionic
flow according to their electrochemical gradients. They play a
key role in generating membrane potential and function in
diverse cellular activities, such as signal transduction, neurotrans-
mitter release, muscle contraction, hormone secretion, volume
regulation, growth, motility, and apoptosis. More than 400 ion
channel genes have been identified.1 Channelopathies are a
genetic or acquired heterogeneous group of disorders that
involve ion channels’ dysfunction. Ion channels are responsible
for various nervous system disorders, such as generalized epi-
lepsy with febrile seizures, familial hemiplegic migraine, episodic
ataxia (EA), hyperkalemic or hypokalemic periodic paralysis,
and myotonic or paramyotonic disorders. Encoded by more
than 70 genes, potassium channels make up the largest group of
ion channels found in virtually all cells of the human body.2
Mutations in the potassium voltage-gated channel subfamily A
(KCNA1) gene have been identified that cause a range of signs
and symptoms affecting the nervous system, such as episodic
ataxia type 1 (EA1) with or without myokymia, isolated myo-
kymia, and epilepsy.3
We present an interesting child with a KCNA1 gene muta-
tion who presented with episodes of prolonged stiffness of both
lower limbs, mimicking paroxysmal nonkinesogenic dyskinesia
(PNKD).
Case Report
The study was approved by the Institutional Review Board of
Wayne State University. Written informed consent from the
legal guardian was obtained for all aspects of the study, the
including videos (Video S1, Video S2). A 5-year old boy pre-
sented with intermittent stiffness of the legs bilaterally associated
with pain. The first episode occurred at 3 years of age in the
evening while he was sitting on the couch. The episode started
with vomiting followed by painful, bilateral stiffening of the
lower extremities without any jerking. He remained alert dur-
ing the episode. However, he was not able to walk due to mus-
cle stiffness and pain. He was taken to the emergency
department. Metabolic workup was normal. He was discharged
home, and he slept with continuing leg stiffness. On waking up
in the morning, his symptoms resolved. He had multiple such
episodes of 2 to 12 hours’ duration occurring every few weeks
to every few months preceded and/or followed by headache/
vomiting and usually triggered by stress and fatigue (Video S1,
Video S2). In between episodes, he was completely normal.
Birth and developmental history was unremarkable. There was
no family history of migraine, seizure, or episodic muscle stiff-
ness. He had normal physical and neurological examinations in
between spells.
Blood count, electrolytes, creatine kinase, and thyroid profile
were normal. Serum amino acid, acylcarnitine profile, lactate,
pyruvate, and urine organic acid levels taken in between and
during the episodes were within normal limits. Paraneoplastic
panel was negative. Prolonged video electroencephalographic
(EEG) monitoring during the spell was normal as well as the
interictal EEG. Brain and spine magnetic resonance imaging
(MRI) was unremarkable. An extensive nerve-conduction study
was normal, and a needle electrode examination was limited
due to pain, but no myotonic or myokymic discharges were
noted. Considering the prolonged episodes of forceful, involun-
tary muscle contraction involving both lower limbs, the episode
resembled dystonia. Considering the possibility of PNKD, an
empiric trial of clonazepam was tried without improvement of
symptoms. After proper genetic counseling, whole-exome
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sequencing was undertaken through GeneDx whole-exome
analysis (GeneDx, Gaithersburg, MD) using genomic DNA iso-
lated from whole blood of the patient and both parents. The
Agilent Clinical Research Exome kit (Agilent Technologies,
Santa Clara, CA) was used to target the exonic regions and
flanking splice junctions of the genome. These targeted regions
were sequenced simultaneously by massive parallel sequencing
on a sequencing system with 100-base-pair paired-end reads.
The bidirectional sequence was assembled, aligned to reference
gene sequences based on human genome build GRCh37/
UCSC hg 19 (University of California Santa Cruz [UCSC]
Genomics Informatics Group, UCSC Genomics Institute, Santa
Cruz, CA), and analyzed for sequence variants using a custom-
developed analysis tool. A capillary sequencing method was
used to confirm all potentially pathogenic variants identified in
samples from the patient and relatives. This sequencing identi-
fied the presence of a heterozygous R86Q variant (an arginine
[R] to glutamine [Q] substitution at position 86), coding variant
c.257 G>A (a guanine [G] to alanine [A] substitution at position
257) in the KCNA1 gene, which is implicated in EA1. In addi-
tion, the patient was heterozygous for the de novo N404K vari-
ant (an asparagine [N] to lysine [K] substitution at position 404)
of uncertain significance in the period circadian clock 2 (PER2)
gene, which is involved in circadian rhythm. Both parents have
been tested, and the mother is heterozygous for the KCNA1
R86Q variant, but she has no symptoms. With the diagnosis of
K-channelopathy, the patient was started on acetazolamide at
15 mg/kg daily, which provided dramatic relief of the symp-
toms without any recurrence for more than 10 months.
Discussion
EA is a genetically heterogeneous disorder. There are at least 7
different types of EA, and 2 are common: EA1 and EA2.3
Whereas EA2 is caused by mutation in the calcium voltage-gated
channel subunit a1 A (CACNA1A) gene on chromosome 19p13,
EA1 is a K-channelopathy caused by heterozygous mutation in
the potassium channel gene KCNA1 on chromosome 12p13.3
EA1 may have a broad spectrum of symptoms like ataxia and
myokymia. During attacks, additional symptoms may be
reported, including vertigo, blurred vision, diplopia, nausea,
headache, diaphoresis, body stiffening, and difficulty breathing.4
Since the first description of EA1, the phenotypic spectrum
of the disease has widened considerably. Some affected individ-
uals may also display delayed motor development, choreoa-
thetosis, carpal spasm, cognitive dysfunctions, expressive
language delay, and inability to learn a motor task. A short-sleep
phenotype and cataplexy have also recently been reported.4
PNKD is an autosomal-dominant disorder of early childhood
with a frequency of attacks that varies from 3 per day to 2 per
year. The attack may start with focal or generalized, dystonic or
choreoathetotic movements, usually triggered by fatigue, alcohol,
caffeine, and emotional excitement, and may last for minutes to
hours. During the attack, the patient remains conscious and con-
tinues to breathe normally. The acute attack is typically relieved
by sleep. Clonazepam is the treatment of choice, and almost 80%
of patients show an excellent response.5 In our patient, the infre-
quent episodes of hour-long stiffening of legs, provoked by stress
and fatigue and relieved after sleep, pointed to the initial possibil-
ity of PNKD. Muscle stiffness, in a more episodic manner, has
been well described in K-channelopathies as defective function of
the K-channel in the muscle membrane that may delay the repo-
larization phase of action potential formation. The muscle mem-
brane, thus, may remain depolarized for a longer duration,
producing muscle stiffness. Muscle stiffness lasting for minutes to
hours can be a close mimicker of dystonia, and even more so in
the episodic dystonia observed in patents with PNKD.
In our patient, the clinical manifestations, characterized by
severe pain, muscle cramps, and leg stiffness preceded or fol-
lowed by headache and vomiting, pointed to the possibility of a
channelopathy, which later was confirmed by whole-exome
sequencing.6 The R86Q variant in the KCNA1 gene has not
been reported previously as a pathogenic or benign variant.
Because incomplete penetrance has been reported for KCNA1
gene mutations in EA, the presence of an R86Q variant in an
asymptomatic mother is quite plausible. R86Q appears to be
extremely rare in the population and, to our knowledge, has
not been reported previously in any existing database. Although
not all rare variants are pathogenic, the very low frequency of
this variant in the population supports the hypothesis that the
R86Q variant is pathogenic. R86Q is a semiconservative substi-
tution that may affect secondary protein structure. The R86Q
amino acid is evolutionally conserved throughout vertebrates. In
silico analyses have predicted that it is probably damaging. This
change is not observed in known healthy cohorts from the
National Heart, Lung, and Blood Institute Exome Sequencing
Project and the Database of Single Nucleotide Polymorphisms.
These findings suggest a pathogenic role for the mutation. To
our knowledge, this is the first description of a KCNA1 gene
mutation without ataxia or myokymia but with prolonged stiff-
ness of the legs.3 We propose expanding the phenotypic expres-
sion of KCNA1 gene mutations to include a prolonged period
of stiffness in the limbs, mimicking PNKD.
Conclusion
PNKD-like symptoms consisting of prolonged episodes of leg
stiffness without ataxia or myokymia can be a manifestation of
EA type 1. Severe pain in the limbs affected by episodic dys-
tonic posturing that persists during sleep points to channelopa-
thy as the etiology.
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Supporting Information
Videos accompanying this article are available in the supporting
information here.
Video S1. A video obtained during a typical spell shows
involuntary muscle contraction of muscles in the lower limbs,
leading to stiff posturing without any associated chorea, atheto-
sis, or tremor. Of note, the child was distressed due to pain and
was unable to use both lower limbs during the spell.
Video S2. A second video shows persistent, painful, stiff
posturing of the lower limbs with lack of movement.
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